Globus Medical has delivered a strong multi year share price run, and the question now is whether that performance lines up with what its earnings can reasonably support. With the stock recently closing at US$81.26, investors are asking if the current P/E and related earnings metrics still tell a comfortable story at this level.
-
Over the past 3 years the stock has gained 76.7%, which puts real pressure on the idea that earnings power needs to keep up with a much higher market value.
-
An investigation into potential fiduciary duty breaches by Globus Medical's leadership may influence how shareholders think about capital allocation and corporate governance, both of which can shape the quality and reliability of future earnings.
-
The analysts covering Globus Medical have run their own numbers. See what analysts think Globus Medical's shares could be worth .
The stock's next move may depend on whether Globus Medical's current price can be explained by its earnings today and what those earnings reasonably point to over time.
If you want to test the same earnings question you are asking of Globus Medical across a wider field, scan through 26 high quality undervalued stocks .
Does Globus Medical Look Undervalued on Earnings?
The P/E ratio is a useful starting point for a business like Globus Medical that already generates earnings. On this measure, the stock trades on about 20.4x earnings, which is below the wider medical equipment industry's average of roughly 27.0x and well under the peer group closer to 39.0x. That sets the share price at a discount to what investors are currently paying for similar healthcare hardware businesses.
A fair value model that adjusts the P/E for Globus Medical's own margins, size, sector and risk profile points to a higher multiple than where the shares change hands today, which leans toward an undervalued reading on this metric. Despite the ongoing fiduciary duty investigation, the market is not attaching a premium valuation and instead prices the stock below both tailored and simple peer benchmarks. Explore the numbers behind Globus Medical's P/E valuation .
The Globus Medical Narrative: What Would Justify Today's Price?
Narratives for Globus Medical pick up where this valuation puzzle leaves off by spelling out which paths for revenue, profitability and earnings would need to play out for the current share price to look either conservative or stretched. Each one sets out the assumptions behind its own fair value view rather than only giving a single multiple, so you can compare those inputs with Globus Medical's reported results over time. These sit on Simply Wall St's Community page.
One of the top community narratives on Globus Medical: 19% undervalued
"Disciplined capital allocation, including use of roughly half of free cash flow for share repurchases, a debt free balance sheet with US$840.5 million of cash and securities…"
Discover why this Narrative puts Globus Medical at 19% undervalued .
One more piece of the Globus Medical puzzle
Before forming a full view on Globus Medical, it helps to look at who is steering the business and how their incentives are structured, because that relationship can shape future decisions in powerful ways. See who runs Globus Medical and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GMED .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
